Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):293-296. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0101

View: 1701 Download: 50

Review

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 3756 Download: 212 Web of Science: 5 Crossref: 10

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 9220 Download: 647 Web of Science: 39 Crossref: 44

Editorial

Another oral antiviral treatment, but still far away from hepatitis B virus cure

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

View: 3922 Download: 101 Web of Science: 5 Crossref: 5

Original Article

Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Jeong Won Jang, Jin Seoub Kim, Hye Seon Kim, Kwon Yong Tak, Heechul Nam, Pil Soo Sung, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Lewis R. Roberts

Clin Mol Hepatol. 2021;27(1):207-218. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0115

View: 7121 Download: 258 Web of Science: 23 Crossref: 24

Editorial

Old hepatitis B virus never dies: It just hides itself within the host genome

Jeong-Hoon Lee

Clin Mol Hepatol. 2021;27(1):107-109. Published online December 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0324

View: 4039 Download: 116 Web of Science: 4 Crossref: 3

Original Article

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B

Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um

Clin Mol Hepatol. 2016;22(3):382-389. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0047

View: 12537 Download: 201 Web of Science: 18 Crossref: 19

Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B

Jeong Han Kim, Hee Won Moon, Soon Young Ko, Won Hyeok Choe, So Young Kwon

Clin Mol Hepatol. 2014;20(3):274-282. Published online September 25, 2014

DOI: https://doi.org/10.3350/cmh.2014.20.3.274

View: 6992 Download: 43 Web of Science: 3 Crossref: 2

The Korean Journal of Hepatology Elsewhere

Growing attention to an old marker, hepatitis B surface antigen, in the natural history of chronic hepatitis B

Jeong Won Jang

Clin Mol Hepatol. 2010;16(3):342-346. Published online September 30, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.3.342

View: 6179 Download: 59 Crossref: 1

1

Predictors for virologic response in management of chronic hepatitis B

Jung Min Lee, M.D. Sang Hoon Ahn, M.D.-

Clin Mol Hepatol. 2010;16(1):1-4. Published online March 26, 2010

DOI: https://doi.org/10.3350/kjhep.2010.16.1.1

View: 4263 Download: 29 Crossref: 1

3

Comparison of Lamivudine-induced HBsAg Loss rate according to age in children with chronic hepatitis B

Jung Mi Kim , Byung Ho Choe , Mi Ae Chu , Seung Man Cho

Clin Mol Hepatol. 2009;15(2):168-178. Published online June 30, 2009

DOI: https://doi.org/10.3350/kjhep.2009.15.2.168

View: 4597 Download: 47 Crossref: 4

1

Prevalence and Clinical Implications of Occult Hepatitis B Virus Infection

Sung Won Cho

Clin Mol Hepatol. 2006;12(2):136-139. Published online January 1, 1970

View: 2790 Download: 17

1 |

Viewed By 5153	MAFLD: How is it different from NAFLD?
Viewed By 4900	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4874	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4581	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4567	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search